fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      53   |   54   |   55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2007-03-08 Galapagos (Belgium)
Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV (Belgium)
  other
See details
2007-03-01 KineMed (USA)
Roche (Switzerland)
KineMarker® technology
This technology measures the on-mechanism activity of compounds in whole body systemsz in animals and man.
R&D
See details
2007-03-01 Vivalis (France)
Fort Dodge Animal Health (USA)
EBx® cell lines for production of viral vaccines licensing
See details
2007-02-28 Molecular Partners (Switzerland)
Roche (Switzerland)
DARPins (Designed Ankyrin Repeat Proteins) / not disclosed R&D
See details
2007-02-26 Graffinity (Germany)
Amgen (USA)
  R&D
other
See details
2007-02-22 Cobra Biomanufacturing (UK)/Advaxis (USA)
Lovaxin C® (therapeutic cervical cancer vaccine) / cervical cancer manufacturing
See details
2007-02-20 TransTech Pharma (USA)
Novo Nordisk (Denmark)
glucokinase activator (GKA) program
(These drug candidates were jointly discovered with Novo Nordisk) / diabetes
licensing
See details
2007-02-14 Acambis (UK)
Sanofi-Pasteur (France)
vaccine ChimeriVaxJE® / Japanese encephalitis manufacturing
commercialization/ distribution
marketing/ promotion
See details
2007-02-12 Micromet (Germany/USA)
Morphotek (USA)
antibody targeting an antigen with potential activity for the treatment of certain cancers, including melanoma. / certain cancers, including melanoma licensing
See details
2007-02-07 Vivalis (France)
Sanofi Pasteur (France)
EBx® cell lines licensing
See details
2007-02-06 UCB (Belgium)
Imclone Systems (USA)
CDP-791 (a pegylated of antibody fragment against vascular endothelial growth factor (VEGF) receptor-2. / non-small-cell lung cancer other
See details
2007-02-06 Jerini (Germany)
Baxter (USA)
Targets associated with haemophilia, with development potential for non-intravenous therapies / Haemophilia R&D
See details
2007-02-06 KineMed (USA)
Bayer Healthcare (Germany)
disease targets /   R&D
development
See details
2007-02-05 Nautilus Biotech (France)
Wyeth (USA)
recombinant Factor IX / Haemophilia B R&D
licensing
See details
2007-02-05 Elbion (Belgium)
Wyeth (USA)
PDE10 (phosphodiesterase 10) inhibitors / central nervous system (CNS) diseases including schizophrenia R&D
licensing
See details
[<<]      «      53   |   54   |   55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63      »      [65]